- Home
- CUBE vs JAZZ Comparison
CUBE vs JAZZ Comparison
Compare CUBE & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUBE
- JAZZ
- Stock Information
- Founded
- CUBE 2004
- JAZZ 2003
- Country
- CUBE United States
- JAZZ Ireland
- Employees
- CUBE N/A
- JAZZ N/A
- Industry
- CUBE Real Estate Investment Trusts
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- CUBE Real Estate
- JAZZ Health Care
- Exchange
- CUBE Nasdaq
- JAZZ Nasdaq
- Market Cap
- CUBE 9.5B
- JAZZ 8.4B
- IPO Year
- CUBE 2004
- JAZZ 2007
- Fundamental
- Price
- CUBE $42.04
- JAZZ $122.92
- Analyst Decision
- CUBE Buy
- JAZZ Strong Buy
- Analyst Count
- CUBE 12
- JAZZ 13
- Target Price
- CUBE $49.33
- JAZZ $187.15
- AVG Volume (30 Days)
- CUBE 1.8M
- JAZZ 1.3M
- Earning Date
- CUBE 04-24-2025
- JAZZ 04-30-2025
- Dividend Yield
- CUBE 4.95%
- JAZZ N/A
- EPS Growth
- CUBE N/A
- JAZZ 41.75
- EPS
- CUBE 1.72
- JAZZ 8.65
- Revenue
- CUBE $1,068,730,000.00
- JAZZ $4,068,950,000.00
- Revenue This Year
- CUBE $0.59
- JAZZ $7.30
- Revenue Next Year
- CUBE $5.77
- JAZZ $4.01
- P/E Ratio
- CUBE $24.45
- JAZZ $14.21
- Revenue Growth
- CUBE 1.31
- JAZZ 6.12
- 52 Week Low
- CUBE $39.80
- JAZZ $99.06
- 52 Week High
- CUBE $55.14
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- CUBE 51.25
- JAZZ 32.69
- Support Level
- CUBE $40.70
- JAZZ $137.74
- Resistance Level
- CUBE $42.32
- JAZZ $142.64
- Average True Range (ATR)
- CUBE 0.90
- JAZZ 3.87
- MACD
- CUBE -0.01
- JAZZ -2.12
- Stochastic Oscillator
- CUBE 58.95
- JAZZ 0.45
About CUBE CubeSmart
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Most of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. The company derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.